All In Biotech

Drug Trial Radar · NCT06058377

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,680

Planned (sponsor's estimate)

Start

Nov 27, 2023

Primary completion

May 31, 2032

Study completion May 31, 2032

Sponsor

Sponsor type
NIH
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Conditions

  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Hormone Receptor-Positive Breast Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo optional collection of tissue and/or blood

  • CyclophosphamideDrug

    Given IV

  • DoxorubicinDrug

    Given IV

  • DurvalumabBiological

    Given IV

  • Genetic TestingOther

    Undergo MammaPrint testing

  • MammographyProcedure

    Undergo mammography

  • PaclitaxelDrug

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Breast cancer event-free survival (BC-EFS)Time frame: Up to 10 years after completion of study treatment

Locations

565 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Recruiting

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Palo Alto Medical Foundation-Fremont

    Fremont, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Memorial Medical Center

    Modesto, California · Recruiting

  • City of Hope Newport Beach

    Newport Beach, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Desert Regional Medical Center

    Palm Springs, California · Recruiting

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California · Recruiting

  • Huntington Memorial Hospital

    Pasadena, California · Recruiting

  • Sutter Roseville Medical Center

    Roseville, California · Recruiting

  • Sutter Medical Center Sacramento

    Sacramento, California · Recruiting

  • SWOG

    Sacramento, California · Recruiting

  • Zuckerberg San Francisco General Hospital

    San Francisco, California · Active not recruiting

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California · Recruiting

  • Mills Health Center

    San Mateo, California · Recruiting

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California · Recruiting

  • Saint John's Cancer Institute

    Santa Monica, California · Recruiting

  • Providence Medical Foundation - Santa Rosa

    Santa Rosa, California · Recruiting

  • Sutter Pacific Medical Foundation

    Santa Rosa, California · Recruiting

  • Providence Santa Rosa Memorial Hospital

    Santa Rosa, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California · Recruiting

Showing 40 of 565 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.